Fulltext

Direct medical costs of type 2 diabetes and its complications in Switzerland

Schmitt-Koopmann, Irmgard ; Schwenkglenks, Matthias ; Spinas, Giatgen A. ; Szucs, Thomas D.

In: The European Journal of Public Health, 2004, vol. 14, no. 1, p. 3-9

Ajouter à la liste personnelle
    Titre
    • Direct medical costs of type 2 diabetes and its complications in Switzerland
    Auteur
    • Schmitt-Koopmann, Irmgard. Division of Medical Economics, University Hospital, Zürich, Switzerland (currently none)
    • Schwenkglenks, Matthias. Hirslanden Research, Zürich, Switzerland
    • Spinas, Giatgen A.. Division of Endocrinology and Diabetes, University Hospital, Zürich, Switzerland
    • Szucs, Thomas D.. Hirslanden Research, Zürich, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • The European Journal of Public Health, 2004, vol. 14, no. 1, p. 3-9. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:297938
    Summary
    Background: This paper analyses the direct medical costs of type 2 diabetes and its complications in Switzerland. Methods: Individual healthcare resource consumption related to type 2 diabetes and its complications was determined retrospectively in 1479 non-incident and non-dying patients over 12 months (1998-1999). Literature-derived attributable risks were used to correct for non-diabetes related macrovascular disease. Results: A total of 111 primary care physicians from 19 cantons throughout Switzerland participated. Their diabetic patients on average had 10.3 consultations per year related to this disease (95% CI: 10.0-10.7). Patients spent on average 2.7 days (95% CI: 2.2-3.3) per year in hospital due to diabetes and diabetes-related complications. Mean annual type 2 diabetes-related direct medical costs per patient amounted to CHF 3,508 / € 2,323 (95% CI: CHF 3,140-3,876 / € 2,080-2,567). They were particularly high in patients with insulin treatment or with complications. After application of attributable risks and a correction for the use of adjuvant materials, costs were CHF 3,324 / € 2,201. Assuming 250,000 patients with type 2 diabetes in Switzerland leads to an estimate of CHF 0.88 billion spent for this disease and its complications in 1998. This represents a share of about 2.2% of the country's total healthcare expenditures. Conclusion: These findings demonstrate the high economic importance of type 2 diabetes and its complications in Switzerland